Literature DB >> 2137844

A structural characterization of the Mo3 activation antigen expressed on the plasma membrane of human mononuclear phagocytes.

I F Mizukami1, S D Vinjamuri, R D Trochelman, R F Todd.   

Abstract

Mo3 is an activation Ag expressed by human monocytic cells after stimulation in vitro by PMA, LPS, certain cytokines, and muramyl dipeptide. The structural characterization of Mo3 has been made possible by the development of a mAb (anti-Mo3f) that immunoprecipitates Mo3 from Nonidet P-40 lysates of radiolabeled PMA-stimulated U-937 cells and LPS-activated monocytes. On SDS-PAGE (nonreducing conditions) of anti-Mo3f immunoprecipitates, U-937 Mo3 is a single broad band of 39 to 66 kDa, whereas monocyte Mo3 is smaller with an apparent molecular mass of 32 to 56 kDa. Under reducing conditions, there is an increase in the m.w. of both species of Mo3 suggesting the existence of internal disulfide bonds. Mo3 is a glycoprotein with carbohydrate of the N-linked complex type as evidence by a reduction in m.w. by 40 to 50% after treatment with endoglycosidase F or N-glycanase; neuraminidase treatment produces a 3-kDa reduction in m.w. Deglycosylated Mo3 isolated from U-937 and monocytes have similar m.w. suggesting that the molecular heterogeneity of the native Mo3 may be due to differences in glycosylation. Mo3 is sensitive to phosphatidylinositol-specific phospholipase C with the release of native Mo3 from the surface of PMA-stimulated U-937 cells. These results indicate that Mo3 is a member of the glycosylphosphatidylinositol-linked family of surface glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137844

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Plasminogen activation in healing human wounds.

Authors:  B M Schäfer; K Maier; U Eickhoff; R F Todd; M D Kramer
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

2.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

3.  Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.

Authors:  Andrei L Kindzelskii; Imran Amhad; Donald Keller; M-J Zhou; Richard P Haugland; B A Garni-Wagner; Margaret R Gyetko; Robert F Todd; Howard R Petty
Journal:  Histochem Cell Biol       Date:  2004-03-20       Impact factor: 4.304

4.  Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.

Authors:  A E May; S M Kanse; L R Lund; R H Gisler; B A Imhof; K T Preissner
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.